Cogent Biosciences, Inc. Payments of Stock Issuance Costs
Cogent Biosciences, Inc. (COGT) reported Payments of Stock Issuance Costs of $11.60 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-07.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2024-05-07
- Cogent Biosciences, Inc. payments of stock issuance costs for the quarter ending 2024-03-31 was $11.60M.
- Cogent Biosciences, Inc. payments of stock issuance costs for the quarter ending 2018-12-31 was $0.00, a 100.00% decline year-over-year.
- Cogent Biosciences, Inc. payments of stock issuance costs for the quarter ending 2018-09-30 was $0.00.
- Cogent Biosciences, Inc. payments of stock issuance costs for the quarter ending 2018-06-30 was $1.49M.
- Cogent Biosciences, Inc. payments of stock issuance costs for fiscal 2020 was $7.27M.
- Cogent Biosciences, Inc. payments of stock issuance costs for fiscal 2018 was $2.06M, a 160.58% increase from fiscal 2017.
- Cogent Biosciences, Inc. payments of stock issuance costs for fiscal 2017 was $789.00K.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|
| 2024-03-31 | $11.60M 10-Q · filed 2024-05-07 | |||
| 2020-12-31 | $7.27M 10-K · filed 2021-03-16 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | $0.00 derived: sum of 2 quarters · filed 2020-03-26 | $1.49M derived: sum of 3 quarters · filed 2020-03-26 | $2.06M 10-K · filed 2020-03-26 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $1.49M derived: sum of 2 quarters · filed 2019-11-12 | $2.06M 10-Q · filed 2019-11-12 | $2.83M derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-06-30 | $1.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12 | $2.06M 10-Q · filed 2019-08-12 | $2.83M derived: sum of 3 quarters · filed 2019-08-12 | |
| 2018-03-31 | $563.00K 10-Q · filed 2019-05-13 | $1.34M derived: sum of 2 quarters · filed 2019-05-13 | ||
| 2017-12-31 | $779.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-28 | $789.00K 10-K · filed 2019-03-28 | ||
| 2017-09-30 | $10.00K 10-Q · filed 2018-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |